Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.3752W HIGH $18.22
Volume
2.73 M
Value Traded
10.45 M
Short % Float
16.89%
Days to Cover
1.9
+11.88%Week
-10.32%1 Month
+25.39%3 Month
+13.12%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
754.88 M
EPS (TTM)
-4.32
P/E Ratio
-
Ent. Value
452.72 M
Total Shares
67.34 M
Float Shares
49.11 M
Insiders
23.67%
Institutions
58.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DNA Catalyst Timeline
Dated clinical, regulatory and corporate events for Ginkgo Bioworks Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ginkgo Bioworks Holdings, Inc.
70Total events
4Upcoming
17Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Ginkgo to provide in-kind autonomous lab access to NSF X-Labs researchers
▲Partnership / LicenseCorporate
Ginkgo Datapoints enters agreement with Lilly TuneLab to provide discovery data generation services
▲Grant / FundingCorporate
Ginkgo awarded subcontract for up to $17.5M under ARPA-H GIVE program for ESCALATOR
▲Partnership / LicenseCorporate
Collaboration with OpenAI using GPT-5 for experiment design; achieved 40% improvement in Cell-Free Protein Synthesis
▲Partnership / LicenseCorporate
Awarded BARDA BioMaP-Consortium project agreement up to $22.2M for monoclonal antibody biomanufacturing and anti-filovirus medical countermeasure
anti-filovirussource ↗
▲Partnership / LicenseCorporate
Q4 2025 partnerships with ARPA-H, University of Illinois Urbana-Champaign, Carnegie Mellon, Agricen, Deep Origin and more
▲Restructuring LayoffsCorporate
Achieved $250 million annualized cost reduction target three months ahead of schedule
▼Restructuring LayoffsCorporate
Reduction in force estimated to achieve over $85M annualized savings by mid-2025
●Quarterly UpdateCorporate
Updated full year 2025 revenue guidance: Total revenue $167-$187 million
▲Other Regulator MilestoneEx-US Regulatory
Awarded $29 million contract by ARPA-H for distributed manufacturing of essential medicines
▲Restructuring LayoffsCorporate
Restructuring achieved $205 million annualized run-rate cost reduction as of Q1 2025
▲Partnership / LicenseCorporate
Awarded up to $9.4M partnership with Carnegie Mellon University for ARPA-H REACT program
●Manufacturing MilestoneCMC / Inspection
Consolidation of Foundry operations into core facilities including Biofab1
▼Restructuring LayoffsCorporate
Acceleration of site consolidation initiatives, exiting facilities in Cambridge, MA and Europe by year end 2024
▲Milestone PaymentCorporate
Delivered major research milestone for Merck deal; Ginkgo to receive $9M cash fee expected in Q4 2024
●Restructuring LayoffsCorporate
Restructuring: achieved $190M annualized cost reduction run-rate; target $250M by end of Q3 2025
▲Partnership / LicenseCorporate
Signed contract for Antibody Developability product from Ginkgo Datapoints with top biopharma company
▲Partnership / LicenseCorporate
Signed new deal with Novo Nordisk for discovery and development of proteins and expanded collaboration on expression systems
◆Quarterly UpdateCorporate
Reaffirmed full year 2024 total revenue guidance of $170-$190 million
▲Partnership / LicenseCorporate
New collaboration with Syngenta Crop Protection to develop microbial strain for secondary metabolite
▲Milestone PaymentCorporate
Delivered major technical milestone for large pharmaceutical customer
▼Restructuring LayoffsCorporate
Reduction in force impacting 35% of workforce commenced in June 2024
▼Restructuring LayoffsCorporate
Received NYSE continued listing standard notice due to stock price below $1
▲Partnership / LicenseCorporate
Partnership with Qatar Free Zones Authority and Doha Venture Capital for CUBE-D
◆Quarterly UpdateCorporate
Plans to report Q4 and full year 2023 financial results in February 2024
●Quarterly UpdateCorporate
Full Year 2024 Guidance: 100-120 new Cell Programs, $215-235M total revenue
▼Restructuring LayoffsCorporate
Reduction in labor expenses of at least 25% including reduction in force
▲Partnership / LicenseCorporate
Grant from Bill & Melinda Gates Foundation for measles forecasting model
Past FDA Catalysts and PDUFA Decisions
How DNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every DNA program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kelly Jason RDirector, Officer (See remarks) | Sell | -45,682 129,065 held | $10.14 | 10/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0 % | 361.65 K | 36.49 K |
DNA Institutional Ownership Trends
DNA Short Interest
Shares sold short, counted twice a month.
16.89%
Short % of Float
of tradable shares sold short
8.3M
Shares Sold Short
+13.4% vs prior count
1.9 Low
Days to Cover
trading days of normal volume to buy every short share back
4.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DNA ranks across every disease it competes in
Competitive Position is a premium feature
See how DNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDNA News
-DNA
Oct 29, 2026▼ -12%today
Ginkgo Bioworks Announces Date of Third Quarter 2026 Results Presentation
Ginkgo Bioworks announced it will present third-quarter 2026 financial results on November 5, 2026. The post-market session begins at 4:30 p.m. ET and includes a Q&A segment. The company will provide webcast details on its investor relations website. A replay of the event will also be made available to the public.
Read more →-DNA
Oct 8, 2026▲ +14.6%on this news
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
Ginkgo Bioworks has announced its collaboration with the National Science Foundation's X-Labs program by providing access to its autonomous laboratory in Boston. This initiative, valued at $1.5 billion, aims to support independent research teams over the next decade. The announcement was made by Michael Kratsios at the Science: A New Golden Age Summit in Washington, D.C.
Read more →-DNA
Oct 8, 2026▲ +14.6%on this newsshared move
Ginkgo Bioworks Cybersecurity and Incident Response
Ginkgo Bioworks reported a cybersecurity incident involving unauthorized access to data from its former biosecurity business. The company has engaged a third-party cybersecurity team for investigation and has notified affected customers. No disruption to core operations has occurred, and the company is cooperating with federal law enforcement.
Read more →-DNA
Oct 8, 2026Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
Araceli Biosciences and Ginkgo Bioworks have integrated the Endeavor high-content imaging system into Ginkgo's Nebula lab. This collaboration enhances drug discovery by providing real-time cellular imaging and analysis. The Endeavor can process a 1536-well plate in under four minutes, significantly improving data generation for AI models in drug development.
Read more →-DNA
Sep 16, 2026Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
Ginkgo Bioworks has announced a partnership with Lilly TuneLab to enhance drug discovery through AI and machine learning. This collaboration will allow Ginkgo Datapoints to provide data generation services, leveraging Lilly's extensive proprietary research data. The partnership aims to bridge the gap between AI models and laboratory data, fostering innovation in biotech.
Read more →-DNA
Sep 15, 2026Ginkgo Bioworks to Build an Autonomous Lab at Novo’s New U.S. R&D Site in Waltham
Ginkgo Bioworks has been selected to construct an autonomous lab at Novo's new R&D site in Waltham, Massachusetts. This partnership builds on their existing collaboration and reflects a trend towards automation in life sciences. The lab will utilize Ginkgo's Reconfigurable Automation Cart and integrated software to enhance research efficiency.
Read more →-DNA
Sep 10, 2026Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
Ginkgo Bioworks has secured a subcontract worth up to $17.5 million from ARPA-H's GIVE program. This initiative focuses on developing a continuous-flow manufacturing system for RNA medicines. Ginkgo will collaborate with Waterfall Scientific to advance this transformative project, which aims to improve individualized medicine production.
Read more →-DNA
Aug 5, 2026▼ -9.3%on this news· ran to -20% by day 3
Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland
Ginkgo Bioworks reported a 48% decline in second quarter 2026 revenue, totaling $20 million, alongside a net loss of $57 million. Despite these financial challenges, the company secured government contracts to build autonomous labs at prestigious institutions, including MIT and Caltech. Ginkgo's Nebula lab is scaling rapidly, indicating a strong position in the autonomous lab market.
Read more →-DNA
Aug 5, 2026Ginkgo Bioworks Expands Autonomous Lab Network to Caltech, MIT, Maryland and Northwestern
Ginkgo Bioworks announced the expansion of its autonomous lab network to four prestigious institutions: Caltech, MIT, UMD, and Northwestern. Supported by the NSF and MLSC, these labs will utilize Ginkgo's robotic systems for automated experiments. This initiative aims to enhance biotechnology education and research capabilities across the country.
Read more →-DNA
Aug 3, 2026▲ +10.5%on this newsshared move
Ginkgo Bioworks and Acies Bio Partner to Expand Global Access to High-Performance Aspergillus niger Strains for Protein Production
Ginkgo Bioworks and Acies Bio have partnered to enhance access to engineered Aspergillus niger strains for protein production. This collaboration combines Ginkgo's advanced microbial strains with Acies' bioprocess development capabilities, allowing for a streamlined transition from strain development to scaled manufacturing. The partnership aims to improve efficiency and reduce costs in protein production.
Read more →-DNA
Jul 30, 2026Ginkgo Bioworks Announces Date of Second Quarter 2026 Results Presentation
Ginkgo Bioworks will host a presentation on August 5, 2026, to discuss its second quarter results for the period ending June 30, 2026. The event will include a Q&A session for investors. Details will be available on the company's investor relations website, along with a replay of the session.
Read more →-DNA
May 7, 2026Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Ginkgo Bioworks reported its first quarter financial results for 2026, showing a significant revenue decline of 49% year-over-year, attributed to the divestiture of its Biosecurity business and ongoing restructuring. The company aims to expand its autonomous lab, Nebula, which is positioned at the forefront of scientific innovation. Despite the challenges, Ginkgo maintains a strong cash position of $373 million.
Read more →-DNA
Apr 30, 2026▲ +12.8%on this news· ran to +29% by day 3
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
Ginkgo Bioworks has announced a presentation and Q&A session scheduled for May 7, 2026, to discuss its business performance for the first quarter of 2026. The event will begin at 4:30 p.m. ET, and details will be available on the company's investor relations website. Investors can submit questions in advance via social media or email.
Read more →-DNA
Feb 26, 2026Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business
Ginkgo Bioworks has announced its financial results for Q4 and FY 2025, highlighting a 25% decline in total revenues year-over-year. The company reported a net loss of $(313) million for the year, although this was an improvement from the previous year's $(547) million loss. Ginkgo is shifting its focus towards autonomous labs and has agreed to divest its non-core biosecurity business, which will allow for greater investment in its autonomous lab offerings. The company remains in a strong cash position, ending 2025 with $423 million.
Read more →-DNA
Nov 6, 2025Ginkgo Bioworks Reports Third Quarter 2025 Financial Results Ginkgo provides an update on its third quarter financial results
Ginkgo Bioworks announced its financial results for the third quarter of 2025, revealing a substantial decline in revenues compared to the previous year. Total revenue was reported at $39 million, down 56%, with a notable decrease in Cell Engineering and Biosecurity segments. The company's net loss increased to $(81) million, largely due to a prior year non-cash revenue adjustment. Despite these setbacks, Ginkgo maintains a positive outlook for the year, reaffirming its revenue targets and highlighting strategic partnerships that could bolster its position in advancing biotechnology.
Read more →-DNA
Aug 7, 2025Ginkgo Bioworks Reports Second Quarter 2025 Financial Results
Ginkgo Bioworks announced its financial results for the second quarter of 2025, reporting a total revenue of $50 million, a decrease from $56 million in the previous year. Despite the drop in total revenue, the company saw an 8% increase in Cell Engineering revenue primarily driven by demand from biopharma and government sectors. Ginkgo successfully achieved its $250 million cost reduction target ahead of schedule, reflecting operational efficiencies. However, the Biosecurity revenue fell significantly, indicating challenges in that segment of the business.
Read more →-DNA
May 21, 2025▼ -7.4%on this news
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
Ginkgo Bioworks announced the appointment of Steven Coen as Chief Financial Officer following Mark Dmytruk's resignation. Coen, who joined Ginkgo as Chief Accounting Officer in 2023, brings over 30 years of financial experience from various industries. His promotion aims to ensure continuity in the financial leadership of the company as it strives for cost reductions and aims for Adjusted EBITDA breakeven by the end of 2026.
Read more →-DNA
May 6, 2025▼ -6.8%on this news
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Ginkgo Bioworks has reported its Q1 2025 financial results, revealing a total revenue of $48 million, a 27% increase compared to the previous year. The company's focus on restructuring has led to a significant reduction in net losses, with an adjusted EBITDA increase from $(117) million in the prior year to $(47) million. Ginkgo secured a $29 million contract from ARPA-H to innovate in essential medicine manufacturing, while maintaining a goal of achieving $250 million in cost reductions by September 2025. The company continues to navigate a complex operational landscape amidst its ongoing restructuring.
Read more →-DNA
Feb 25, 2025Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target
Ginkgo Bioworks reported its financial results for the fourth quarter and full year 2024, showcasing a 29% growth in Cell Engineering revenue over 2023. While total revenue decreased by 10% for the year primarily due to changes in Biosecurity revenue, the company achieved significant cash flow improvements and reduced GAAP net losses. Ginkgo remains optimistic about its restructuring efforts and projections for 2025 revenue in both Cell Engineering and Biosecurity segments.
Read more →About Ginkgo Bioworks Holdings, Inc.
Headquarters27 DRYDOCK AVENUE, BOSTON, MA, 02210
BIOPHARMAWATCH ELITE PLUS
Trade the next DNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime